Phio Pharmaceuticals
PHIO
7 hedge funds and large institutions have $259K invested in Phio Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 2 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
22% less funds holding
Funds holding: 9 → 7 (-2)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
49% less capital invested
Capital invested by funds: $511K → $259K (-$252K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SG Americas Securities
New York
|
+$35.6K |
| 2 |
Renaissance Technologies
New York
|
+$10.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$109K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$33K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$29.3K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$18K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$2.09K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
SG Americas Securities
New York
| $194K | +$35.6K | +17 | +17% |
|
|
CH
2
CVI Holdings
Wilmington,
Delaware
| $26K | -$109K | -52 | -76% |
|
|
3
Renaissance Technologies
New York
| $13K | +$10.5K | +5 | +167% |
|
|
4
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $9K | -$29.3K | -14 | -70% |
|
|
5
UBS Group
Zurich,
Switzerland
| $9K | -$2.09K | -1 | -17% |
|
6
Vanguard Group
Malvern,
Pennsylvania
| $7K | – | – | – |
|
7
Morgan Stanley
New York
| $1K | – | – | – |
|
|
KFS
8
Kelly Financial Services
Braintree,
Massachusetts
| $1 | – | – | – |
|
|
9
Citadel Advisors
Miami,
Florida
| – | -$33K | -14 | Closed |
|
|
TSS
10
Two Sigma Securities
New York
| – | -$18K | -8 | Closed |
|
PHIO Hedge Fund Activity: Q3 2019 in Review
7 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q3 2019, worth a combined $259K — down 49% from $511K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of PHIO and 0 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 2 added.
The largest buyer was SG Americas Securities, adding an estimated $35.6K. The largest seller was CVI Holdings, cutting an estimated $109K.
- 7 institutional investors held Phio Pharmaceuticals (PHIO) as of Q3 2019, down from 9 in Q2 2019.
- Funds reported $259K of Phio Pharmaceuticals stock for Q3 2019, down 49% quarter-over-quarter.
- 0 funds opened new Phio Pharmaceuticals positions in Q3 2019 and 2 closed out, a net change of -2 holders.
- The largest Phio Pharmaceuticals buyer in Q3 2019 was SG Americas Securities, an estimated $35.6K added.
- The largest Phio Pharmaceuticals seller in Q3 2019 was CVI Holdings, an estimated $109K sold.
Based on aggregated 13F filings for Q3 2019.